MAGE-C2 TCR T Cell Trial to Treat Melanoma and Head and Neck Cancer

Single-centre, first-in-man phase I/II trial to demonstrate safety and efficacy of MAGE-C2/HLA-A2 TCR T cells (MC2 TCR T cells) in advanced melanoma (MEL) and head-and-neck carcinoma (HNSCC).

Trial Details

NCT ID

NCT04729543

Phase

PHASE1 / PHASE2

Sponsor

Erasmus Medical Center

Status

RECRUITING

Cancer Type

Melanoma

Interventions

Adoptive therapy with autologous MC2 TCR T cells

Locations (sample)

Rotterdam, Netherlands|51.9225,4.47917

Key Eligibility Criteria

Written informed consent;
Age ≥ 18 years;
One of the following three malignancies:
Previously treated for unresectable or metastatic cutaneous or mucosal melanoma for whom no standard treatment is available (anymore);

For full eligibility, visit ClinicalTrials.gov.

Check If You May Be Eligible

Trialify translates complex eligibility criteria into plain yes-or-no questions to help you understand if this trial might be right for you.

Find Melanoma Trials on Trialify →